Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helong Zhang

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Cancer Biology & Medicine|March 12, 2021
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trialTianqing Chu, Jun Lu, Minghong Bi, et al.
International Journal of Clinical Oncology|February 19, 2022
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LAThomas John, Hiroshi Sakai, Satoshi Ikeda, et al.
JTO Clinical and Research Reports|October 18, 2021
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407Ying Cheng, Li Zhang, Jie Hu, et al.
BMC Cancer|April 11, 2016
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancerYan Sun, Ying Cheng, Xuezhi Hao, et al.
Cancer Medicine|November 7, 2023
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III studyLikun Chen, Jose David Gomez Rangel, Timucin Cil, et al.
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2023
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III TrialHuiping Li, Yan Huang, Zhendong Chen, et al.
JTO Clinical and Research Reports|October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping AlterationsShun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 StudyXinghao Ai, Qiming Wang, Ying Cheng, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Cancer Biology & Medicine|March 12, 2021
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trialTianqing Chu, Jun Lu, Minghong Bi, et al.
International Journal of Clinical Oncology|February 19, 2022
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LAThomas John, Hiroshi Sakai, Satoshi Ikeda, et al.
JTO Clinical and Research Reports|October 18, 2021
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407Ying Cheng, Li Zhang, Jie Hu, et al.
BMC Cancer|April 11, 2016
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancerYan Sun, Ying Cheng, Xuezhi Hao, et al.
Cancer Medicine|November 7, 2023
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III studyLikun Chen, Jose David Gomez Rangel, Timucin Cil, et al.
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2023
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III TrialHuiping Li, Yan Huang, Zhendong Chen, et al.
JTO Clinical and Research Reports|October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping AlterationsShun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 StudyXinghao Ai, Qiming Wang, Ying Cheng, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
Pageof 11